[CAR T-cell therapy and bispecific antibodies for relapsed/refractory large B-cell lymphoma].

Abstract

While many cases of large B-cell lymphoma (LBCL) can be cured with initial treatment, some patients experience relapse or are refractory to treatment. Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies can be used for relapsed or chemotherapy-refractory LBCL. This review highlights the latest evidence regarding CAR T-cell therapy and bispecific antibodies for relapsed or refractory LBCL.